Evolution of Peptide Drug Biopharmaceutics

被引:1
|
作者
Ivanov, V. T. [1 ]
Deigin, V. I. [1 ]
机构
[1] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia
关键词
peptide synthesis; biological activity; cyclopeptides; peptidomimetics; ORALLY-ACTIVE PEPTIDOMIMETICS; THERAPEUTIC PEPTIDES; FUTURE; PHARMACOKINETICS; DISCOVERY; PERMEABILITY; PLATFORM; PROTEIN;
D O I
10.1134/S1068162023030123
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
-Peptides are low-molecular-weight substances involved in numerous physiological processes, such as growth and development of the organism, stress, regulation of the emotional state, sexual behavior, and immune responses. Most peptides act as ligands for proteins, the interaction with which leads to highly selective effects. Such properties, as well as a low toxicity, allow us to consider peptides as potential effective drugs. The preparation of peptide drugs became possible at the beginning of the 20th century after the development of a method of their selective synthesis. Despite the success of the synthesis of the first peptide drugs, many issues associated with an increase in the stability, bioavailability, half-life, and the ability to move through the cell membranes remain unresolved. The review considers the historical path of development of the synthesis and production of peptides, and discusses modern approaches to the creation of peptide drugs and their application in biopharmaceutics, including in the development of original peptide drugs in Russia.
引用
收藏
页码:422 / 434
页数:13
相关论文
共 50 条
  • [41] TASKS OF BIOPHARMACEUTICS
    FURST, W
    ARCHIV DER PHARMAZIE UND BERICHTE DER DEUTSCHEN PHARMAZEUTISCHEN GESSELSCHAFT, 1970, 303 (04): : B144 - &
  • [42] PRINCIPLES OF BIOPHARMACEUTICS
    BARR, WH
    AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION, 1968, 32 (05) : 958 - &
  • [43] Provisional in-silico biopharmaceutics classification ( BCS) to guide oral drug product development
    Wolk, Omri
    Agbaria, Riad
    Dahan, Arik
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1563 - 1575
  • [44] Possibility of extending biopharmaceutics classification system based biowaiver to BCS class Ha drug
    Khalid, Farah
    Hassan, Syed Muhammad Farid
    Noor, Rabia
    Zaheer, Kamran
    Hassan, Fouzia
    Muhammad, Iyad Naeem
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 32 (05) : 2065 - 2073
  • [45] Feasibility of biowaiver extension to Biopharmaceutics Classification System Class III drug products - Cimetidine
    Jantratid, E
    Prakongpan, S
    Amidon, GL
    Dressman, JB
    CLINICAL PHARMACOKINETICS, 2006, 45 (04) : 385 - 399
  • [46] Biopharmaceutics, formulations and exposure
    Srinivas, Nuggehally R.
    ASIAN JOURNAL OF PHARMACEUTICS, 2010, 4 (01) : 1 - 3
  • [47] Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development
    Mehta, Mehul U.
    Uppoor, Ramana S.
    Conner, Dale P.
    Seo, Paul
    Vaidyanathan, Jayabharathi
    Volpe, Donna A.
    Stier, Ethan
    Chilukuri, Dakshina
    Dorantes, Angelica
    Ghosh, Tapash
    Mandula, Haritha
    Raines, Kimberly
    Dhanormchitphong, Pariban
    Woodcock, Janet
    Yu, Lawrence X.
    MOLECULAR PHARMACEUTICS, 2017, 14 (12) : 4334 - 4338
  • [48] Technical feasibility of placing biopharmaceutics before in vivo evaluation in drug discovery programs.
    Jasti, B
    Wiegand, R
    Keyes, K
    Grieshaber, C
    Valeriote, F
    Parchment, R
    CLINICAL CANCER RESEARCH, 2000, 6 : 4498S - 4498S
  • [49] Lack of Effect of Antioxidants on Biopharmaceutics Classification System (BCS) Class III Drug Permeability
    Yu, Yuly Chiang
    Lu, Dongmei
    Rege, Bhagwant
    Polli, James E.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 113 (08) : 2215 - 2222
  • [50] Structure-based evolution of a peptide IAP inhibitor into a small molecule drug candidate
    Varney, Michael D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241